Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 5/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799336 | 0.89 | MAPT (0.42) | MAPTTP53 | |
| SCHEMBL4802055 | 0.88 | FSCN1 (0.38) | FSCN1PDE10APTGDR2PPARGALKBH1 | |
| SCHEMBL4804162 | 0.86 | FSCN1 (0.40) | FSCN1PDE10APTGDR2PPARGALKBH1 | |
| SCHEMBL4808461 | 0.85 | SMN1; SMN2 (0.47) | FSCN1PDE10APTGDR2PPARGMAPT | |
| SCHEMBL4803688 | 0.85 | FSCN1 (0.39) | FSCN1PDE10APTGDR2PPARGALKBH1 | |
| SCHEMBL4806877 | 0.84 | FSCN1 (0.39) | FSCN1PTGDR2PPARGMAPT | |
| SCHEMBL5258224 | 0.81 | DDR1 (0.36) | FSCN1PDE10APPARGP2RX7F2RL3 | |
| SCHEMBL2943369 | 0.81 | CNR2 (0.43) | FSCN1PTGDR2F2RL3MAPT | |
| SCHEMBL2946889 | 0.81 | FSCN1 (0.42) | FSCN1PDE10APTGDR2PPARGALKBH1 | |
| SCHEMBL2943243 | 0.80 | ALDH1A1 (0.40) | FSCN1PDE10APTGDR2ALKBH1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1756103-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC | 2005-12-15 | — | — | US | disclosed |
| WO-2005103003-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | FSCN1 4841/4885PDE10A 2565/4885PTGDR2 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.